We specialize in antibody discovery, protein engineering, synthetic biology, and digital biotechnology and work with a multitude of protein scaffolds and conjugation techniques. These include human antibodies, nanobodies, and other binding proteins that we utilize as precision molecules to combat and diagnose diseases, engineer microbiomes, and solve challenges within industrial biotechnology.

We believe that science should be conducted for the benefit of society. To achieve this, our research focuses both on scientific and technological insight, as well as translational aspects and practical applications. Moreover, we actively engage in innovation and entrepreneurship, and have successfully spun out several biotech companies.

On the technology side, the section focuses on developing monoclonal antibodies and nanobodies with special binding properties, oligoclonal antibody and nanobody mixtures and designed antigens. These antibodies and nanobodies can be used for broad neutralization of multiple targets at low doses, or selective targeting of critical key factors involved in disease and pathogenesis. Designed antigens, on the other hand, can be used for novel vaccine applications and for specialized antibody discovery. We employ high-throughput and automated epitope mapping to precisely engineer broad-spectrum biotherapeutics with enhanced specificity and reduced off-target effects. We also employ conjugation techniques to develop antibody-drug conjugates and advanced protein engineering tools to develop antibodies with dynamic binding properties modulated by environmental cues, such as pH shifts.

Our expertise in these fields allows us to design advanced biotherapeutics, diagnostic tools, and molecules for feed, food, and biocontrol purposes. We see antibodies and antigens as precision engineering tools that can be used to design molecules that target specific anatomical sites, that are robust under harsh conditions, or that can be manufactured at ultra-low cost.